Maggi Enrico
Ordinario di Medicina Interna, Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze.
G Ital Med Lav Ergon. 2017 Nov;39(3):168-171.
In the last decades the knowledge on pathogenetic mechanisms of allergic diseases extraordinarily improved with relevant clinical outputs. From the '90yrs we know that Th2 cells are essential for allergic inflammation, since they produce type 2 cytokines, recognise allergens, induce IgE switch on B cells and recruit mastcells and eosinophils into tissues for maintaining the flogosis.
Recently a new subset of innate immunity (ILC2) have been shown to amplify the allergic inflammation.
The chronicity of respiratory allergy is characterised by tissue signals which address T cell to a "Th2 high"- (ILC2/Th2 responses) or a "Th2 low" (ILC3/Th17 responses) endotype, with a BAL prevalence of eosinophils or neutrophils, respectively.
This double response is essentially due to T effector cell plasticity, modulated by microenvironmental signals. The discovery of new endotypes, diagnosed by selective biomarkers and cured by biological agents, will open the era of personalised medicine also for respiratory allergic disorders.
在过去几十年中,关于过敏性疾病发病机制的知识有了显著进步,并产生了相关的临床成果。自20世纪90年代以来,我们知道Th2细胞对于过敏性炎症至关重要,因为它们产生2型细胞因子,识别过敏原,诱导B细胞发生IgE类别转换,并将肥大细胞和嗜酸性粒细胞募集到组织中以维持炎症。
最近发现一种新的固有免疫亚群(ILC2)可放大过敏性炎症。
呼吸道过敏的慢性炎症具有组织信号特征,这些信号使T细胞转向“高Th2”(ILC2/Th2反应)或“低Th2”(ILC3/Th17反应)内型,其支气管肺泡灌洗中嗜酸性粒细胞或中性粒细胞的患病率分别较高。
这种双重反应主要归因于T效应细胞的可塑性,其受微环境信号调节。通过选择性生物标志物诊断并使用生物制剂治疗的新内型的发现,也将开启呼吸道过敏性疾病个性化医学的时代。